Connecticut Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Connecticut Wealth Management's VRTX Position: Q2 2026 in Review
Connecticut Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.19% in Q2 2026, selling an estimated $2.22K and leaving 2,648 shares worth $1.32M. The position accounts for 0.05% of the portfolio, ranked #134.
Connecticut Wealth Management first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.41M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Connecticut Wealth Management held 2,648 shares of Vertex Pharmaceuticals worth $1.32M as of Q2 2026.
- Connecticut Wealth Management sold 5 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.22K.
- Vertex Pharmaceuticals made up 0.05% of Connecticut Wealth Management's portfolio in Q2 2026, its #134 holding.
- Connecticut Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
- Connecticut Wealth Management's Vertex Pharmaceuticals position peaked at $1.41M in Q1 2025.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Connecticut Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.